MA
SLXN

Montag & Associates’s Silexion Therapeutics SLXN Stock Holding History

Montag & Associates’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765 Hold
300
– – ﹤0.01% 937
2026
Q1 		$3.84K Hold
300
– – ﹤0.01% 810
2025
Q4 		$5.76K Hold
300
– – ﹤0.01% 809
2025
Q3 		$10.2K Buy
+300
New +$24.9K ﹤0.01% 765

Other funds holding SLXN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Montag & Associates's SLXN Position: Q2 2026 in Review

Montag & Associates held its Silexion Therapeutics (SLXN) position steady in Q2 2026 at 300 shares worth $765. The position accounts for ﹤0.01% of the portfolio, ranked #937.

Montag & Associates first reported a position in SLXN in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.2K in Q3 2025. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • Montag & Associates held 300 shares of Silexion Therapeutics worth $765 as of Q2 2026.
  • Montag & Associates left its Silexion Therapeutics share count unchanged in Q2 2026.
  • Silexion Therapeutics made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #937 holding.
  • Montag & Associates first reported a position in Silexion Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Montag & Associates's Silexion Therapeutics position peaked at $10.2K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.